An observational study in Glaucoma and Ocular Hypertension, sponsored by Mario Stirpe. Enrolling by invitation at 5 sites in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Mario Stirpe · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.
Among the 53 studies in Glaucoma with a site in Italy, this one is the 4th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, and was the 46th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:
Laboratoires Thea · Sites in Italy
Ages 18+
Centervue SpA · Sites in Italy
Ages 40–90
Fondazione G.B. Bietti, IRCCS · Sites in Italy
Ages 18+
Mario Stirpe · Sites in Italy
Ages 18+
Association for Innovation and Biomedical Research on Light and Image · Sites in Italy, Germany, Spain and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 7 · Phase 4 14
First in 1993; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 101 across 386 observational studies indexed under Glaucoma.
Median enrollment 64 across the 39 interventional studies, 200 across the 13 observational. Of the 38 that completed or were terminated, 6 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 53 have an industry lead sponsor. The 10 most frequent:
Mario Stirpe is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Mario Stirpe has 2 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07006194Università degli Studi 'G. d'Annunzio' Chieti e PescaraNicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP) | 2026-12-31 |
| NCT07206628Laboratoires TheaReal-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP® | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Glaucoma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study involving patients with glaucoma, those with ocular hypertension and healthy subjects.
The aim of the study is the long term evaluation of functional, vascular and morphological changes in glaucoma and ocular hypertensive patients, compared to healthy subjects, to analyze the temporal relationship of these changes.
This is an observational study involving patients with glaucoma, those with ocular hypertension and healthy subjects.
The aim of the study is the long term evaluation of functional, vascular and morphological changes in glaucoma and ocular hypertensive patients, compared to healthy subjects, to analyze the temporal relationship of these changes.
Secondary aims of the study are:
During the study patients will undergo BCVA assessment, biomicroscopy, IOP measurement, CCT measurement, gonioscopy, visual field test, optic nerve head and macula OCT scan, OCT angiography scan, fundoscopy, every 6 months (for glaucoma and ocular hypertensive patients) and every 12 months (for healthy subjects). The study lasts 3 years.
Four Italian glaucoma center will partecipate in this study, in addition to the promoter.
Four hundred patients and 100 healthy subjects will be involved.
People attending the hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iagnosis of primary glaucoma (open or closed angle) or secondary glaucoma (pseudoexfoliative or pigmentary) defined by the presence of a glaucomatous defect of the optic nerve and/or a perimetric glaucomatous defect as defined by European guidelines
Diagnosis of ocular hypertension (defined by the presence of intraocular pressure values ≥22 mmHg, optic nerve and visual field examination within normal limits).
No optic nerve disease IOP \< 21 mmHg
Rate of disease progression
Rate of progression of functional, morphological and vascular parameters, calculated on the basis of tests repeated over time
Time frame: Up to 3 years
Rate of disease progression in relation to age
Rate of progression of functional, morphological and vascular parameters, in relation to age
Time frame: Up to 3 years
Rate of disease progression in relation to myopia
Rate of progression of functional, morphological and vascular parameters, in relation to myopia
Time frame: Up to 3 years
Rate of disease progression in relation to demographic data
Rate of progression of functional, morphological and vascular parameters, in relation to clinical and demographic factors collected at baseline (visual acuity, axial length, diagnosis, sex, stage of the disease, etc.)
Time frame: Up to 3 years
Quality of life in glaucoma and ocular hypertensive patients
Quality of life questionnaire (National Eye Institute Visual Function Questionnaire-25) scores over time. The minimum value is 0, the maximum value is 100. Higher score means a better outcome.
Time frame: Up to 3 years
Plan to share: No
Started Nov 2024 (actual). Primary completion is estimated for Nov 2028, 48 months after the start.
Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 48 months is close to that.
Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mario Stirpe